



ORDERING PHYSICIAN

Bob Doctor MD
123 Land End Road
Anywhere, UT 84098

SPECIMEN

Specimen Type: Tissue Slide
Tissue: Prostate
Biopsy Date: Oct 9, 2012
TRF Received: Oct 12, 2012
Accession Date: Oct 16, 2012
Report Date: Oct 21, 2012

PATIENT

Name: M, Robert
Date of Birth: Jul 8, 1944
Patient ID: 198447
Gender: Male
Accession #: 99999999-BLD
Requisition #: 12345678

Block(s) Analyzed: GS95672 A11


Prolaris Score: 1.8

Considerably More Aggressive Than Average AUA Low Risk


Interpretation: The Prolaris Score of 1.8 indicates that this cancer is considerably more aggressive than the average cancer in the American Urology Association (AUA) Low Risk category.

10-Year Prostate Cancer-Specific Mortality Risk: 5% (95% CI:2-11%)

Interpretation: The patient has a 10-year mortality risk of 5% if managed conservatively. Mortality risks could be altered by various therapeutic interventions.



The above chart illustrates the AUA Low Risk category, which is composed of patients with varying degrees of cancer aggressiveness. Cancer aggressiveness can be stratified within this category based upon Prolaris Scores, which are indicated below the graph.



US Distribution Percentile: >99% (For AUA Low Risk)

Interpretation: >99% of patients in the AUA Low Risk category have a lower Prolaris Score.

CLINICO-PATHOLOGIC FEATURES USED FOR ANALYSIS

PSA Prior to This Biopsy: 5.2
Clinical T Stage: T1c
Gleason Score: 3+3=6

Patients with similar clinico-pathologic features, as defined by their CAPRA score, have the same a priori 10-year prostate cancer-specific mortality risk. The addition of the Prolaris Score further differentiates this risk, as illustrated in the above graph, which is specific to this patient's CAPRA score. The orange line depicts the relationship between the Prolaris Score and the mortality risk with the 95% confidence interval indicated by dashed lines and the patient's Prolaris Score indicated by the orange dot.

CLINICO-PATHOLOGIC FEATURES USED FOR ANALYSIS

Patient Age: 67 % Positive Cores: 8% (1/12)
PSA Prior to This Biopsy: 5.2 Gleason Score: 3+3=6
Clinical T Stage: T1c

Note: Clinico-pathologic parameters are provided by the healthcare provider and have not been verified by Myriad.

CONFIDENTIAL



# Prolaris® Biopsy Test Result



## Prolaris

### ORDERING PHYSICIAN

**Bob Doctor MD**  
123 Land End Road  
Anywhere, UT 84098

### SPECIMEN

Specimen Type: **Tissue Slide**  
Tissue: **Prostate**  
Biopsy Date: **Oct 9, 2012**  
TRF Received: **Oct 12, 2012**  
Accession Date: **Oct 16, 2012**  
Report Date: **Oct 21, 2012**

### PATIENT

Name: **M, Robert**  
Date of Birth: **Jul 8, 1944**  
Patient ID: **198447**  
Gender: **Male**  
Accession #: **99999999-BLD**  
Requisition #: **12345678**

\* The thresholds between the "Considerably Less Aggressive", "Less Aggressive", "Consistent", "More Aggressive", and "Considerably More Aggressive" intervals are one unit of Prolaris Score apart, with the "Consistent" interval centered at the median Prolaris Score as of April 10, 2013. These intervals are based upon Prolaris Scores observed among patients tested at Myriad and may be adjusted in the future to reflect additional observations. The hazard ratio for death from prostate cancer for one unit of Prolaris Score is 1.9 (95% CI 1.3, 2.8).<sup>2-3</sup> The aggressiveness intervals are intended to help refine risk assessment. Specific therapeutic decisions should take into account all relevant clinical parameters including a patient's age, overall health, etc.

### References

- 1) American Urological Association. Guideline for the management of clinically localized prostate cancer: 2007 update.
- 2) Data on file. Myriad Genetics, Inc. 2012.
- 3) Cuzick J *et al.* Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. *Br J Cancer.* 106(6):1095-9, 2012.
- 4) Cooperberg MR *et al.* Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. *J Natl Cancer Inst.* 101(12):878-87, 2009.

**Analysis Description:** Analysis is performed on total RNA extracted from FFPE blocks, from which prostatic adenocarcinoma tissue is identified by H&E analysis performed by a pathologist. This test utilizes quantitative PCR analysis to assay 31 cell cycle genes and 15 control genes, the expression of which is used to calculate a Prolaris Score, which can be combined with clinical information to generate the 10-year prostate cancer-specific mortality risk (see the Technical Specifications for additional details). Adjuvant hormonal therapy and radiation treatment are known to affect Prolaris Scores, potentially resulting in incorrect test interpretation. Patients receiving these treatments prior to biopsy are not suitable candidates for Prolaris testing. This test is not validated for the analysis of tumor samples from individuals with PSA levels >100 ng/ml. If you have any questions regarding this report, please contact Medical Services at ProlarisMed@Myriad.com or 1-800-469-7423.

### Authorized Signature:

Benjamin B. Roa, Ph.D.  
Diplomate ABMG  
Laboratory Director

Richard J. Wenstrup, MD  
Diplomate ABMG  
Chief Medical Officer

Karla R. Bowles, Ph.D.  
Diplomate ABMG  
Laboratory Director Pharmacogenetics

Kathryn A. Kolquist, M.D.  
Diplomate ABP, ABMG  
Laboratory Director Anatomic Pathology

The Technical Specifications summary (available at [myriadpro.com](http://myriadpro.com)) describes the analysis, method, performance characteristics, nomenclature, and interpretive criteria of this test. This test may be considered investigational in some states. This test was developed and its performance characteristics determined by Myriad Genetic Laboratories. It has not been reviewed by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.